Cadonilimab (AK104) Plus Chemotherapy as First-line Treatment in Non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients With Programmed Cell Death Ligand 1 (PD-L1) Negative - Trial NCT06001151
Access comprehensive clinical trial information for NCT06001151 through Pure Global AI's free database. This Phase 2 trial is sponsored by Qian Chu and is currently Recruiting. The study focuses on Carcinoma, Non-Small-Cell Lung. Target enrollment is 49 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Qian Chu
Tongji Hospital
Timeline & Enrollment
Phase 2
Aug 07, 2023
Aug 31, 2027
Primary Outcome
12-month progression-free-survival (PFS) rate
Summary
This is a single arm, multi-center clinical trial. Target population is advanced or
 metastatic non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients with Programmed Cell
 Death Ligand 1 (PD-L1) negative, aiming to evaluate the efficacy and safety of the
 combination therapy of Cadonilimab and chemotherapy. Cadonilimab is a PD-1/CTLA-4 bi-specific
 antibody.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06001151
Non-Device Trial